Aurobindo Pharma Limited reported a 32% year-on-year increase in consolidated net profit to ₹10.33 billion for the quarter ended June 30, 2026, driven by robust revenue growth and the recent acquisition of Lannett Company LLC. Consolidated revenue from operations rose to ₹91.5 billion compared to ₹77.9 billion in the same quarter last year. The Board of Directors, meeting on August 5, 2026, also approved a Scheme of Amalgamation to merge two step-down subsidiaries, Eugia Steriles Private Limited and Eugia SEZ Private Limited, into wholly-owned subsidiary Eugia Pharma Specialities Limited, aiming to simplify the corporate structure and reduce overheads.

The Board approved the standalone and consolidated unaudited financial results pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Deloitte Haskins & Sells issued an unmodified conclusion on the limited review of the interim financial information. The merger proposal was disclosed under Regulation 30 of the SEBI LODR Regulations, with the scheme to be filed with the Hon'ble NCLT, Hyderabad. The transaction is classified as a related party transaction but is exempt from related party provisions under Section 188 of the Companies Act, 2013, as it involves wholly-owned subsidiaries.

Financial Performance Highlights

The company's consolidated financial results reflect strong operational momentum, with EBITDA expanding significantly on a year-on-year basis. The following table summarises key consolidated metrics:

Standalone revenue from operations stood at ₹27,995.1 million, a slight decline of 1.7% from ₹28,481.7 million in Q1FY25. However, standalone other income surged to ₹2,418.9 million from ₹837.7 million a year ago, largely due to higher foreign exchange gains. Total expenses decreased to ₹20,333.2 million from ₹21,818.5 million in the prior year period, contributing to the improved bottom line.

What the Numbers Show

The significant divergence between standalone and consolidated performance highlights the material impact of the Lannett Company LLC acquisition, completed on June 29, 2026. While standalone revenue dipped slightly, consolidated revenue and EBITDA both expanded meaningfully on a year-on-year basis, with EBITDA margin improving by 270 basis points to 23.07%. Exceptional items of ₹401.8 million were recorded in the consolidated statement for acquisition-related costs. The rise in other income, particularly foreign exchange gains of ₹526.2 million in the consolidated books versus nil in the prior year, further bolstered profitability.

Strategic Developments and Corporate Actions

The proposed amalgamation of Eugia entities aims to consolidate three companies engaged in manufacturing injectable pharmaceutical products into a single legal entity. This move is expected to eliminate duplicate corporate and administrative functions, reduce costs, and improve treasury management. The turnover for the involved entities for FY26 was as follows:

During the quarter, Aurobindo Pharma incorporated Arrow Pharma Production SAS in France and PT Auro Pharm Indonesia as step-down subsidiaries. The company also acquired a 26% stake in Swarnaakshu Solar Power Private Limited for ₹5.2 million. Subsequent to the quarter end, on July 23, 2026, subsidiary Apitoria Pharma Private Limited approved the acquisition of an 80% interest in the A1 Biochem Group for an enterprise value of USD 17.0 million.

Aurobindo Pharma reported a consolidated net profit of ₹1,032 crore for Q1FY27, a 25.2% increase from ₹824 crore in the same period last year. Revenue from operations grew 16.3% year-on-year to ₹9,150 crore, driven by robust volume gains in Europe and the US, alongside new product launches. The company maintained an operating EBITDA margin of 21.0%, expanding by 60 basis points compared to Q1FY26, while generating free cash flow of US$ 98 million despite significant capital deployment for acquisitions and buybacks.

The unaudited financial results for the quarter ended June 30, 2026, were submitted to the National Stock Exchange of India Limited and BSE Limited on August 5, 2026, under Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. B. Adi Reddy, Company Secretary, signed the disclosure. An investor and analyst call was scheduled for August 6, 2026, to discuss the performance.

Financial Performance

Revenue growth was broad-based across geographies. US formulations revenue rose 8.1% year-on-year to ₹3,770 crore (US$ 399 million), supported by volume gains and ten new product launches. Europe saw a sharper 25.6% increase to ₹2,937 crore (EUR 267 million), accounting for 32.1% of consolidated revenue. Growth markets expanded by 37.7% to ₹1,063 crore (US$ 113 million). The API segment contributed ₹1,049 crore, up 14.6% year-on-year, though it faced sequential softness due to seasonal factors in antibiotics. ARV revenue remained stable at ₹330 crore.

*Operating EBITDA excludes a one-time expense of ₹43 crore related to the derecognition of lease receivables.

Cash Flow and Capital Allocation

Despite heavy capital deployment, Aurobindo Pharma generated free cash flow from business of US$ 98 million in Q1FY27. This was achieved after accounting for normal capex of US$ 40 million. The company utilized cash for the Lannett acquisition (US$ 247 million), share buybacks (US$ 85 million), and new business development capex (US$ 20 million). As of June 30, 2026, the company held a net cash position (including investments) of approximately US$ 42 million. Gross debt stood at US$ 887 million, comprising working capital loans of US$ 800 million and other term loans of US$ 87 million.

What the Numbers Show

The divergence between operating EBITDA growth (20.0%) and net profit growth (25.2%) highlights the impact of non-operating items. While operating margins expanded modestly, the bottom line benefited significantly from other income, which nearly doubled to ₹212 crore from ₹105 crore in Q1FY26, alongside a foreign exchange gain of ₹53 crore. Conversely, the one-time lease derecognition expense of ₹43 crore tempered reported EBITDA figures, though operational profitability remained robust across all key segments. Basic and diluted EPS stood at ₹17.86 per share.

Biosimilars and Contract Manufacturing Updates

CuraTeQ Biologics advanced its regulatory and commercial footprint. The company secured ANVISA GMP certification for Brazil and filed Denosumab biosimilars (FILVIZY and FUGEVY) with the EMA. Commercially, all four MHRA-approved products are now supplying in the UK, with multi-country rollouts underway in Europe and initial entries into Mexico and Algeria. TheraNym, the biologics contract manufacturing arm, inaugurated Unit 1 on June 3, 2026, with qualification activities set for November 2026. Construction on Unit 2, estimated at US$ 180 million, is scheduled to begin in October 2026.